# Nitzan Rosenfeld

Source: https://onco.cc/people/nitzan-rosenfeld/  
OnCo record `nitzan-rosenfeld` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Showed that whole-exome sequencing of blood can track how a cancer evolves, and co-founded Inivata.

## Summary

Nitzan Rosenfeld led the 2013 Nature study showing that exome sequencing of circulating tumour DNA tracks the evolution of resistance across multiple cancers, and the earlier work using tagged-amplicon sequencing to monitor breast cancer, both foundational to liquid biopsy. He developed methods for detecting ctDNA at very low fractions and co-founded Inivata, now part of NeoGenomics. He moved from Cambridge to Barts in 2023.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: ctdna; liquid-biopsy; genomics
- Role: Professor of Cancer Genomics, Barts Cancer Institute; former Senior Group Leader, CRUK Cambridge Institute
- Specialisms: Circulating tumour DNA; Liquid biopsy methods; Cancer genomics; Early detection

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Rosenfeld%20N%5BAuthor%5D%20circulating%20tumor%20DNA

## Connected records

- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- institutions: [Barts Cancer Institute / Barts Health NHS Trust](https://onco.cc/institutions/barts-cancer-institute/), [Cancer Research UK Cambridge Centre / CRUK Cambridge Institute](https://onco.cc/institutions/cruk-cambridge-centre/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/)

---
JSON: https://onco.cc/api/v1/entities/nitzan-rosenfeld.json